CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome

(2012) Kirsty M. Brodie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

NESdb: a database of NES-containing CRM1 cargoes

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis

(2012) Lior Golomb et al.   MOLECULAR CELL

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage

(2011) Pauline J. van der Watt et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

NOTCH1 mutations in CLL associated with trisomy 12

(2011) V. Balatti et al.   BLOOD

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome

(2011) R. E. Tiedemann et al.   CANCER RESEARCH

Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain

(2011) William T. Senapedis et al.   MOLECULAR BIOLOGY OF THE CELL

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status

(2010) J. Quinn et al.   BLOOD

p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma

(2010) Changxia Shao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

(2009) J. G. Turner et al.   CANCER RESEARCH

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD